NCT03816176View on ClinicalTrials.gov

A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

August 22, 2019

Primary Completion Date

December 14, 2022

Study Completion Date

December 14, 2022

Conditions
Invasive MucormycosisInvasive Aspergillosis
Interventions
DRUG

Isavuconazonium sulfate

Intravenous (IV) infusion

DRUG

Isavuconazonium sulfate

Oral capsule

Trial Locations (10)

3000

Site BE32002, Leuven

8035

Site ES34002, Barcelona

9000

Site BE32001, Ghent

20010

Children's National Medical Center, Washington D.C.

28009

Site ES34003, Madrid

28041

Site ES34001, Madrid

60611

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

90027

Children's Hospital, Los Angeles, Los Angeles

90095

University of California - Los Angeles, Los Angeles

92868

Children's Hospital of Orange County, Orange

All Listed Sponsors
lead

Astellas Pharma Global Development, Inc.

INDUSTRY

NCT03816176 - A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants | Biotech Hunter | Biotech Hunter